{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06104306",
            "orgStudyIdInfo": {
                "id": "GS-US-380-6738"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-506660-13",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                }
            ],
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)",
            "officialTitle": "A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "study-of-b-f-taf-in-participants-switching-from-cab-rpv-to-b-f-taf-for-hiv-infection-empower"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-23",
            "studyFirstSubmitQcDate": "2023-10-23",
            "studyFirstPostDateStruct": {
                "date": "2023-10-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gilead Sciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical study is to learn how safe and effective it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels.\n\nThe primary objective of this study is to assess the safety of switching to B/F/TAF in virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular (IM) injections or wishing to switch to oral therapy through Week 12."
        },
        "conditionsModule": {
            "conditions": [
                "HIV-1-infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 35,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "B/F/TAF",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a fixed dose combination of B/F/TAF 50/200/25 mg once daily for 24 weeks",
                    "interventionNames": [
                        "Drug: B/F/TAF"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "B/F/TAF",
                    "description": "Tablets administered without regard to food",
                    "armGroupLabels": [
                        "B/F/TAF"
                    ],
                    "otherNames": [
                        "Biktarvy \u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)",
                    "timeFrame": "First dose up to Week 12"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint)",
                    "timeFrame": "First dose up to Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Plasma Concentrations of Bictegravir (BIC), Cabotegravir (CAB), and Rilpivirine (RPV) at Day 1",
                    "timeFrame": "Day 1"
                },
                {
                    "measure": "Plasma Concentration of BIC, CAB, and RPV at Week 4",
                    "timeFrame": "Week 4"
                },
                {
                    "measure": "Plasma Concentration of BIC, CAB, and RPV at Week 12",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Plasma Concentration of BIC, CAB, and RPV at Week 24",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Proportion of Participants with HIV-1 RNA \u2265 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach",
                    "description": "This outcome measure will be analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data will be excluded in the analysis.",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Proportion of Participants with HIV-1 RNA \u2265 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach",
                    "description": "This outcome measure will be analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data will be excluded in the analysis.",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Proportion of Participants with HIV-1 RNA \u2265 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach",
                    "description": "This outcome measure will be analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation will be treated as HIV-1 RNA \\>= 50 copies/mL (failure) in the analysis.",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Proportion of Participants with HIV-1 RNA \u2265 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach",
                    "description": "This outcome measure will be analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation will be treated as HIV-1 RNA \\>= 50 copies/mL (failure) in the analysis.",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Percentage of Participants with Discontinuation of B/F/TAF by Week 12",
                    "timeFrame": "Up to 12 Weeks"
                },
                {
                    "measure": "Percentage of Participants with Discontinuation of B/F/TAF by Week 24",
                    "timeFrame": "Up to 24 Weeks"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 24",
                    "timeFrame": "First dose up to Week 24"
                },
                {
                    "measure": "HIV Treatment Satisfaction Questionnaire Change (HIVTSQc) Total Score at Week 4",
                    "description": "The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. The total score may range from -33 to +33, based on 11 items. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.",
                    "timeFrame": "Week 4"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* People with HIV-1 (PWH) or provider decision to switch off CAB+RPV IM injections due to intolerance, inconvenience, adverse events (AEs), or willing to switch to (and intention to remain on) daily B/F/TAF\n* Currently virologically suppressed (HIV-1 RNA \\< 50 copies/mL) on CAB+RPV IM injections every 2 months\n* Currently on CAB+RPV IM injections every 2 months and received at least one dose of CAB+RPV IM injection; no missed CAB+RPV injections\n* Ability to receive B/F/TAF up to 7 days prior to the next scheduled dose of CAB+RPV\n* Documented plasma HIV-1 RNA \\< 50 copies/mL during treatment for \u2265 6 months preceding the screening visit\n* No documented or suspected resistance to BIC, emtricitabine (FTC), or tenofovir (TFV).\n\nKey Exclusion Criteria:\n\n* History of B/F/TAF intolerance\n* History of previous INSTI virologic failure including CAB+RPV\n* Requirement for ongoing therapy with any prohibited medications listed in local prescribing information for B/F/TAF starting within 30 days prior to screening until 30 days following the last dose of study drug\n* Have been treated within 3 months of study screening or expected to receive during the study immunosuppressant therapies or chemotherapeutic agents (eg, chronic (at least 4 weeks) systemic steroids, immunoglobulins, and other immune- or cytokine-based therapies)\n* Need for oral antiretroviral therapy (ART) bridge or use of other antiretroviral (ARV) agents prior to starting B/F/TAF on Day 1\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gilead Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-833-445-3230 (GILEAD-0)",
                    "email": "GileadClinicalTrials@gilead.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gilead Study Director",
                    "affiliation": "Gilead Sciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Franco Felizarta, MD",
                    "status": "RECRUITING",
                    "city": "Bakersfield",
                    "state": "California",
                    "zip": "93301",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.37329,
                        "lon": -119.01871
                    }
                },
                {
                    "facility": "BIOS Clinical Research",
                    "status": "RECRUITING",
                    "city": "Palm Springs",
                    "state": "California",
                    "zip": "92262",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.8303,
                        "lon": -116.54529
                    }
                },
                {
                    "facility": "UC San Diego AntiViral Research Center (AVRC)",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Midway Immunology and Research Center",
                    "status": "RECRUITING",
                    "city": "Fort Pierce",
                    "state": "Florida",
                    "zip": "34982",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.44671,
                        "lon": -80.32561
                    }
                },
                {
                    "facility": "Bliss Health",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32806",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Indiana University Infectious Diseases Research",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Boston Medical Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02118",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Las Vegas Research Center",
                    "status": "RECRUITING",
                    "city": "Las Vegas",
                    "state": "Nevada",
                    "zip": "89106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.17497,
                        "lon": -115.13722
                    }
                },
                {
                    "facility": "Saint Michael's Medical Center",
                    "status": "RECRUITING",
                    "city": "Newark",
                    "state": "New Jersey",
                    "zip": "07102",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.73566,
                        "lon": -74.17237
                    }
                },
                {
                    "facility": "MultiCare Rockwood Main Clinic",
                    "status": "RECRUITING",
                    "city": "Spokane",
                    "state": "Washington",
                    "zip": "99202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.65966,
                        "lon": -117.42908
                    }
                },
                {
                    "facility": "Hamilton Health Sciences-SIS Clinic",
                    "status": "RECRUITING",
                    "city": "Hamilton",
                    "zip": "L8L2X2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.25011,
                        "lon": -79.84963
                    }
                },
                {
                    "facility": "University Health Network - Toronto General Hospital",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "zip": "M5G 2C4",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "CHU Bordeaux - Hopital Saint-Andre",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33075",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "APHM - Hospital Sainte Marguerite",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "CHR Orleans",
                    "status": "RECRUITING",
                    "city": "Orleans",
                    "zip": "45100",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.90289,
                        "lon": 1.90389
                    }
                },
                {
                    "facility": "Centre Hospitalier Annecy Genevois",
                    "status": "RECRUITING",
                    "city": "Pringy Cedex",
                    "zip": "74374",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.94622,
                        "lon": 6.12608
                    }
                },
                {
                    "facility": "HU de Strasbourg - Nouvel Hopital Civil",
                    "status": "RECRUITING",
                    "city": "Strasbourg",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.58392,
                        "lon": 7.74553
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study?nctid=NCT06104306"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007239",
                    "term": "Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}